Loading...
Market
What will be the court ruling on whether Vertex's Casgevy fertility support program violates anti-kickback laws by end of 2024?
3
Resolution / Starting Odds
Does not violate • 25%
Violates • 25%
Partially violates • 25%
No ruling • 25%
Court rulings and official announcements from Vertex Pharmaceuticals or the U.S. Department of Health and Human Services
Story
Vertex Pharmaceuticals Sues US Government Over Casgevy CRISPR Treatment Fertility Support Program
Jul 15, 2024, 06:15 PM
Vertex Pharmaceuticals has filed a lawsuit against the U.S. Department of Health and Human Services (HHS), seeking a court declaration that a fertility support program for patients prescribed its gene editing therapy, Casgevy, does not violate federal anti-kickback laws. The CRISPR treatment, which is used to treat sickle cell disease and beta thalassemia, carries a high risk of infertility. Vertex argues that the federal rule blocking access to fertility preservation services for these patients is problematic and seeks permission to pay for fertility treatment for individuals undergoing the Casgevy therapy.
View original story
Similar markets
Yes • 50%
No • 50%
Vertex wins • 25%
US government wins • 25%
Settlement reached • 25%
Case dismissed • 25%
Yes • 50%
No • 50%
Positive • 25%
Negative • 25%
Mixed • 25%
Indifferent • 25%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Appeal denied • 25%
Appeal granted • 25%
Settlement reached • 25%
Case withdrawn • 25%
FTC wins • 25%
FTC loses • 25%
Settlement reached • 25%
Case dismissed • 25%